Pharmacy Times October 14, 2024
Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief

Key Takeaways

  • PBMs have shifted from administrative roles to profit-driven entities, focusing on in-house dispensing and rebate schemes.
  • The FTC has launched investigations into PBM practices, highlighting potential market misalignments and economic rents.
  • Transparency and value-based contracting are essential for PBMs to align with purchaser demands and ensure market functionality.
  • Community pharmacies face closures due to unfavorable PBM contracts, necessitating urgent industry changes to maintain access and sustainability.

PBMS ARE BUSINESSES, DESIGNED TO MAKE A RETURN ON EQUITY AND INVESTMENTS

Nearly every working or retired American owns a piece of a company with a pharmacy benefit manager (PBM). I frequently ask a room of pharmacy owners how many of them log into their brokerage or retirement accounts each...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
Survey Suggests Pharma Industry Still Struggling with Digital Transformation
Will Walgreens’ store closures disrupt its clinical trial aims?
340B Legal Challenges Highlight The Appetite For Innovation That Supports The Program’s Goals
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights

Share This Article